Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients

Trial Profile

A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HH-CYH33 (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical

Most Recent Events

  • 30 Apr 2025 Results evaluating Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 22 Apr 2025 Status changed from recruiting to completed.
  • 04 Jan 2023 Planned End Date changed from 20 Aug 2021 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top